Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.13 +0.19 (+0.76%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
Phio Pharmaceuticals Announces New Chief Financial Officer
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... 
Via Newsfile
Topics Initial Public Offering
Exposures Securities Market
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Pfizer $PFE Beats Earnings Estimates
Pfizer $PFE Beats Earnings Estimates and Raises Full-Year Outlook Amid Cost-Cutting Measures 
Via Chartmill
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
Pfizer shares have advanced 20% over the past three months. 
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals. 
Via InvestorPlace
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
Pfizer reported second-quarter adjusted EPS of $0.60, surpassing the consensus of $0.46. Sales reached $13.28 billion, beating expectations. Analysts highlight Pfizer's robust portfolio, effective... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Pfizer (PFE) Q2 2024 Earnings Call Transcript
PFE earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them. This... 
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
Via Benzinga
Exposures COVID-19
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q2 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Dow Jumps 200 Points; Pfizer Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Pfizer reports Q2 adjusted EPS of $0.60, beating the $0.46 consensus. Sales reached $13.28 billion, driven by acquired products and new launches, despite a decline in Comirnaty. Updated 2024 revenue... 
Via Benzinga
Exposures COVID-19
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks." 
Via Benzinga
Pfizer Inc. Beats Q2 Market Expectations With $13.3 Billion In Revenue
Pfizer Inc. reported a strong Q2 performance in 2024, with total revenues reaching $13.3 billion. 
Via Talk Markets
Pfizer Stock Rises On Earnings Beat, Raised Outlook
The drug giant's EPS fell vs. a year earlier, but revenue topped. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July. 
Via MarketBeat
Topics ETFs
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In
Wall Street is likely to tenaciously hold onto the slender optimism ahead of a slew of earnings from notable companies and the Federal Reserve’s two-day rate-setting meeting that gets underway on... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
10 Best Ultra-High-Yield Dividend Stocks to Consider as Part of a Long-Term Portfolio
These ultra-high-yield dividend stocks could be a great fit for a long-term-oriented portfolio. 
Via The Motley Fool
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
US Stocks Close Mixed Ahead Of Big Earnings, Fed Decision: Investor Optimism Improves Further
Via Benzinga
Topics Economy
Exposures Interest Rates
Procter & Gamble, Microsoft And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.